Trulicity (dulaglutide) / Eli Lilly - LARVOL DELTA

TIRZSEMA-CVOT: Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk (clinicaltrials.gov) - P=N/A | N=100000 | Active, not recruiting | Sponsor: Brigham and Women's Hospital

HEOR • New trial • Cardiovascular • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation. (PubMed, World J Cardiol) - "GLP-1 RAs emerge as a promising and potential alternative for AADs in reduction of incidence of AF. However, further research is required to fully determine their therapeutic potential and long-term cardiovascular effects."

Journal • Atrial Fibrillation • Cardiovascular • Genetic Disorders

Long-Term Outcomes of GLP-1 Use After Liver and Simultaneous Liver Kidney Transplant (WTC 2025) - "Patients were excluded for lack of follow up, exenatide use, or graft loss within 6 months post-transplant...Most patients (76.3%) were on a steroid free regimen at the start of GLP-1 treatment and were either treated with dulaglutide (38%) or semaglutide (35.5%) with mean follow up of 1016 [677-1523] days... This is one of the largest single-center experiences and longest follow up studies of GLP-1 use post liver and SLK transplant. Use of GLP-1 appears to be a safe agent for use in liver and SLK transplant patients with improvements in weight, BMI and A1c. Side effects were common and should be carefully monitored for post-transplant."

Cardiovascular • Diabetes • Metabolic Disorders • Transplantation

Evaluation of GLP-1 Receptor Agonists Use in Post-Kidney Transplant Recipients with Type 2 Diabetes Mellitus (WTC 2025) - "Exclusion criteria included history of other organ transplants or bariatric surgery, pregnant women, prisoners, and patients who were on sirolimus or belatacept...There was no difference in tacrolimus levels between immediate-release or extended-release tacrolimus formulations at all time points... GLP-1RAs did not significantly change tacrolimus levels within 28 days of initiation. GLP-1RAs did not significantly affect HbA1C but did have weight loss benefits in KT patients."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Genetic Disorders • Hypertension • Metabolic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease • Solid Organ Transplantation • Transplantation • Type 2 Diabetes Mellitus

DUP-SURPASS: Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data (clinicaltrials.gov) - P=N/A | N=60000 | Active, not recruiting | Sponsor: Brigham and Women's Hospital

New trial • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study. (PubMed, Clin Nutr) - "While GLP-1 RAs do not show a significant increase in overall psychiatric ADR reporting, findings suggest that clinicians should remain vigilant for potential depressive symptoms and suicidality, particularly in individuals with obesity treated with semaglutide since its approval for weight management."

Adverse events • Journal • CNS Disorders • Depression • Diabetes • Genetic Disorders • Metabolic Disorders • Mood Disorders • Obesity • Psychiatry • Suicidal Ideation • Type 2 Diabetes Mellitus

Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis. (PubMed, World J Diabetes) - "Pharmacotherapy of T2DM with dulaglutide, dapagliflozin, liraglutide, empagliflozin, exenatide, and linagliptin in children is associated with modest reduction of HbA1c. Larger RCTs with longer follow-up durations are needed to guide better therapeutic decision making."

Journal • Retrospective data • Diabetes • Dyslipidemia • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

GLP-1 And Advanced NASH: Impact On Liver Fibrosis Regression (ENDO 2025) - "Tirzepatide outperformed dulaglutide in reducing inflammatory and fibrotic markers...The combination of exenatide and dapagliflozin proved more effective in improving FLI, NLFS, FIB-4, liver transaminases, and insulin resistance... Liraglutide and semaglutide showed convincing effects on NASH resolution, regression of fibrosis, and liver bio-markers relating to inflammation in patients suffering from type 2 diabetes and advanced fibrosis while keeping a safe profile. These results highly encourage the use of these medications for advanced NASH."

Late-breaking abstract • Metastases • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

SURPASS-CVOT: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (clinicaltrials.gov) - P3 | N=13299 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Adverse events • Trial completion • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-experienced Patients With T2D (ENDO 2025) - "This real-world study demonstrated that among GLP-1 RA-experienced patients with T2D, tirzepatide initiators had more index medication fills, greater adherence and longer persistence than semaglutide initiators over the 12-month post-index period."

Clinical • HEOR • Late-breaking abstract • Real-world • Real-world evidence • Diabetes • Type 2 Diabetes Mellitus

Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis. (PubMed, Int J Mol Med) - "In vitro Met-5A cells showed significant upregulation of inflammatory, oxidative stress, intracellular and mitochondrial reactive oxygen species (ROS), fibrotic, intracellular cytoskeletal, apoptotic and epithelial-mesenchymal transition (EMT) biomarkers, and dipeptidyl peptidase 4 (DPP4), following stimulation with a uremic toxin (p-Cresol), PF inducer [chlorhexidine gluconate (CG)] or endotoxin [lipopolysaccharide (LPS)]. At this time point, flow cytometry revealed significantly increased levels of inflammatory cells (CD11b/c+, myeloperoxidase+ and Ly6G+ cells) in the circulation and abdominal fluid, and increased peritoneal permeability in the LPS-induced peritonitis group compared with those in the SC group; these levels were significantly reversed in the LPS-induced peritonitis + dulaglutide group. In conclusion, dulaglutide may effectively maintain peritoneal integrity primarily by suppressing inflammation, oxidative stress, EMT and fibrosis."

Journal • Preclinical • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • CD31 • CDH2 • CTNNB1 • ITGAM • MPO • PECAM1 • SMAD3 • TGFB1 • TNFA • VIM

Levoketoconazole Use Prior to Adrenalectomy (ENDO 2025) - "A one milligram overnight dexamethasone suppression test was abnormal at 2.0 µg/dL...Recorlev®, 150 mg daily was started in December 2023 with Trulicity and metformin discontinued.At a January 2024 follow-up, the Recorlev® dose was increased to 150 twice daily... This is the first documented case of pre-operative use of Recorlev® in a patient undergoing adrenalectomy. The tumor was found to secrete both cortisol and aldosterone. Pre-operative administration of Recorlev® successfully attenuated these hormones, facilitating a smooth surgical procedure and favorable postoperative outcome."

Adrenal Cortex Carcinoma • Asthma • Dyslipidemia • Endocrine Cancer • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Oncology • Respiratory Diseases • Solid Tumor

A case which GLP 1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission (ENDO 2025) - "After surgery, he was administered hydrocortisone 15 mg/day, levothyroxine 75 μg/day replacement therapy, diabetic SGLT2 inhibitors, DPP4 inhibitors, metformin, and pioglitazone, but his BMI worsened to 31.6 and his obesity worsened, and his HbA1c worsened to 12.0%...Calorie restriction and rhGH administration were started to correct obesity (no desire for hypogonadal treatment), and DPP4 inhibitors were discontinued and switched to dulaglutide 0.75mg, but the effect was insufficient with HbA1c in the 8% range and BMI 30.9... This patient with hypopituitarism accompanied by obesity and diabetes had been treated with hormone replacement therapy and conventional oral diabetes medication, however blood glucose and weight were difficult to manage. We reported a case which the long-acting GLP1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission. The administration of GLP-1 receptor agonist..."

Clinical • Diabetes • Endocrine Cancer • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Pain • Pituitary Gland Carcinoma

Perioperative Weight Loss With GLP-1 Receptor Agonists in Patients Receiving Bariatric Surgery (ENDO 2025) - "Adults with obesity who underwent sleeve gastrectomy or gastric bypass were identified and stratified into treatment groups based on the GLP-1 or GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA prescribed (semaglutide, liraglutide, dulaglutide, and tirzepatide) and the timing of prescription in relation to their operation. Patients on GLP-1 receptor agonists both preoperatively and postoperatively relative to bariatric surgery experienced the greatest weight loss. While existing studieshave focused on the use of GLP-1 primarily for weight regain, our findings highlight their potential as adjunctive therapy for weight loss during the critical perioperative period."

Bariatric surgery • Clinical • Surgery • Gastrointestinal Disorder • Genetic Disorders • Obesity

Comparison of Long-Acting and Short-Acting GLP-1 Receptor Agonists on Copeptin in Euvolemic Participants - A Secondary Analysis of Three Prospective Trials (ENDO 2025) - "The primary objective was to compare the effect of a three-week treatment with dulaglutide (GOLD & GATE trials) to a single dose of exenatide (FAST trial) on plasma copeptin release in euvolemic adults. Long- and short-acting GLP-1 RA differ in their effects on copeptin regulation. Long-acting GLP-1 agonists significantly suppress copeptin, likely through a synergistic mechanism, while short-acting GLP-1 RAs appear to stimulate copeptin release. These differing effects may also extend to other GLP-1-related mechanisms with potential high clinical relevance."

Clinical

Metabolic Outcomes Combining Endoscopic Bariatric Procedures and GLP-1 Receptor Agonist Pharmacotherapy in Veterans with Obesity (ENDO 2025) - "Patients were classified into semaglutide monotherapy, GLP1-RA (either Semaglutide, Dulaglutide or Liraglutide) combined with Endoscopic Sleeve Gastroplasty (ESG) or Intragastric Balloon (IGB) at a single urban Veterans hospital. In our local weight management clinic cohort of US veterans with obesity, we observe equivalent weight loss outcomes but reduction in HbA1c with semaglutide monotherapy compared to GLP1-RA+EBMT suggesting additional metabolic benefits. Limitations include small sample size and limited use of semaglutide in the combination groups. Further studies are required to confirm our findings."

Genetic Disorders • Obesity

Is GLP-1 Receptor Agonist Contraindicated In MEN2A Syndrome Despite A Prophylactic Thyroidectomy? (ENDO 2025) - "However, responses in humans and rodents can vary, and current evidence does not support a complete contraindication of GLP-1 receptor agonists in patients with a history of MEN2A syndrome.Case reportA 62-year-old man with T2DM had suboptimal glycemic control despite metformin therapy, with a hemoglobin A1C of 9.7%...His diabetes regimen at that time included dulaglutide and recently initiated sitagliptin 100 mg daily...They also reduce the risk of major cardiovascular events and help slow the progression of chronic kidney disease. Additionally, GLP-1 receptor agonists are often considered to have better compliance and adherence rates than insulin, especially in the long term.ConclusionThere are not enough studies to determine the increased risk or recurrence of hereditary Medullary Thyroid Cancer on long-term use of Dulaglutide therapy, particularly in patients with MEN2A syndrome who have undergone prophylactic thyroidectomy, have negative pathology results, and..."

Late-breaking abstract • Chronic Kidney Disease • Diabetes • Endocrine Cancer • Endocrine Disorders • Hypoglycemia • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • Type 2 Diabetes Mellitus

Perioperative Anesthetic Management in a High-Risk Patient with Pheochromocytoma and Multiple Comorbidities. (ASA 2025) - "57-year-old man with a PMH of CAD s/p stent placement in 2019, ischemic cardiomyopathy with preserved EF, HLD, HTN, CKD (stage 3), T2DM (on insulin, Jardiance, Trulicity) and pheochromocytoma...He was bolused nitroglycerine and started on a precedex infusion pre-induction, reducing his blood pressure. A R IJ Central line was placed, and the case proceeded uneventfully without complications. This case highlights the complexity in managing perioperative blood pressure control and hemodynamics in a patient with pheochromocytoma."

Clinical • Anesthesia • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Endocrine Cancer • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Euglycemic Diabetic Ketoacidosis With Recent Initiation Of A SGLT2 Inhibitor Medication In A Patient With T2D (ENDO 2025) - "The patient was previously on dulaglutide and metformin, however, she was only prescribed empagliflozin for current diabetes management...The patient was discharged with Lantus 20 units and sliding scale insulin (SSI); empagliflozin was discontinued...Additionally, this case emphasizes that EDKA can develop within a few days of initiating a SGLT2 inhibitor even among individuals without type 1 diabetes or insulin deficiency. A delay in diagnosis and treatment of EDKA can lead to worse outcomes including death."

Clinical • Late-breaking abstract • Back Pain • Cardiovascular • Diabetes • Glaucoma • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Ophthalmology • Pain • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Interstitial Granulomatous Dermatitis Induced by Dulaglutide (EADV 2025) - No abstract available

Dermatitis • Dermatology • Immunology

Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-naive Patients With T2D (ENDO 2025) - "In this real-world study, among GLP-1 RA-naive patients with T2D, tirzepatide initiators had more index medication fills, and a greater proportion were adherent to and persistent on index medication than semaglutide initiators over the 12-month post-index period."

Clinical • HEOR • Late-breaking abstract • Real-world • Real-world evidence • Diabetes • Type 2 Diabetes Mellitus

Unilateral Adrenalectomy in a Patient With Overt Cushing Syndrome Caused by Primary Bilateral Macronodular Adrenal Hyperplasia: A Temporizing Measure (ENDO 2025) - "Despite being generally asymptomatic prior to admission, she was subsequently diagnosed with ACTH-independent Cushing syndrome caused by PBMAH, with a positive overnight 1 mg dexamethasone suppression test (cortisol level of 23.2 µg/dL, n<1.8 µg/dL), 24-hour urine cortisol of 291.4 µg/day (4.0-50.0 µg/day) and ACTH level of 6 pg/mL (6-50 pg/mL)...Her hyperglycemia was noted to have improved 1 month post-op, on continued treatment with insulin glargine and dulaglutide. Although PBMAH more commonly presents as mild autonomous cortisol secretion, the patient's 24-hour urine cortisol at the time of diagnosis was nearly 6 times the ULN, consistent with overt Cushing syndrome... Although PBMAH more commonly presents as mild autonomous cortisol secretion, the patient's 24-hour urine cortisol at the time of diagnosis was nearly 6 times the ULN, consistent with overt Cushing syndrome. Despite bilateral adrenalectomy being the recommended treatment..."

Clinical • Cushing’s Disease • Diabetes • Endocrine Disorders • Metabolic Disorders • Nephrology • Pain • Renal Disease • KDM1A

Addition of Dulaglutide to Immunosuppressive Therapy Markedly Reduces Insulin Requirements in a Patient with Insulin Antibody-Mediated Resistance (ENDO 2025) - "The most recent HbA1c is 7.7%, without further episodes of hypoglycemia on a regimen of etanercept (50mg q7d), prednisone (5mg qd), mycophenolate mofetil (1500mg bid), metformin (1000mg bid), empagliflozin (25mg qd), dulaglutide (0.75 mg q10d), glargine insulin (62 units/d), and small doses (<3 units) of aspart insulin as needed with meals. Insulin resistance due to the development of anti-insulin autoantibodies is a rare and challenging condition to treat. This patient's case demonstrates the effectiveness of GLP1-RAs as an adjunctive treatment to decrease insulin resistance and supports a potential immunomodulatory effect of this class of drugs. Further studies should explore the beneficial mechanisms of GLP1-RAs in this autoimmune condition, and its use as a therapeutic option for patients with insulin antibody-mediated resistance."

Clinical • Diabetes • Dyslipidemia • Hypertriglyceridemia • Hypoglycemia • Immunology • Inflammatory Arthritis • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Severe Hypertriglyceridemia

Association of Acute kidney injury with commonly prescribed glucagon-like peptide 1 receptor Agonists: A Pharmacovigilance Analysis (ENDO 2025) - "Background: The advent of innovative pharmacological therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), has transformed the management of type 2 diabetes mellitus (T2DM) by optimizing glycemic control and effectively targeting comorbidities, including obesity and cardiovascular diseases...This study utilized data from the FDA Adverse Event Reporting System (FAERS) to evaluate and compare the real-world association between the most prescribed injectable GLP-1RAs and AKI. The FAERS database was queried on January 30, 2025, using product-specific terms ('Dulaglutide,' 'Exenatide,' 'Liraglutide,' 'Semaglutide,' and 'Tirzepatide') to identify 284,492 adverse event reports, including cases of AKI... FAERS data indicated elevated RORs for AKI with liraglutide, semaglutide, and exenatide, suggesting potential safety concerns. However, causality cannot be confirmed due to inherent limitations of FAERS. Further..."

Adverse events • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • ROR1

Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in Men (ENDO 2025) - "Background: Obesity and type 2 diabetes in men are associated with reduced serum total and free testosterone (T)...Semaglutide, dulaglutide, and tirzepatide were used by 68%, 16%, and 38%, while 27% used more than one therapy... Incretin therapy increases total and free T in men, likely due to weight loss. A 10% weight loss significantly increased the proportion of men with normal testosterone."

Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus